

## Maternal and neonatal colonization with group B streptococci in Ottawa

N.E. MACDONALD,\* MD; A.M.R. MACKENZIE, MD

Group B streptococci are now recognized as an important cause of neonatal sepsis, a theoretically preventable disease. In the period June 1977 to July 1978 there were nine cases of proven group B streptococcal sepsis known to us in the Ottawa region, an area in which there are about 12 000 deliveries per year. Because the institution of rational prophylactic measures demands knowledge of the epidemiologic situation in a particular locality, we undertook the following study of the rates of colonization by this organism in parturient women and their newborn infants in Ottawa.

### Methods

In the fall of 1977, 132 parturient women consecutively admitted to the Ottawa Civic Hospital were studied along with their newborn infants (including one set of twins). Vaginal and rectal swabs were taken from the mothers at the time of admission to the caseroom. Umbilical, groin and ear swabs were taken from the infants within 5 minutes of delivery. All swabs were taken by the caseroom nurses, placed directly in the selective medium described by Baker, Clark and Barrett,<sup>1</sup> and transported to

the laboratory the same day. Organisms were identified as group B streptococci by the CAMP test<sup>2</sup> and by immunodiffusion. The strains were typed by Dr. J.C. Huang, of the Laboratory Centre for Disease Control, Ottawa.

### Results

Colonization by group B streptococci was detected in 26 (20%) of the women and 11 (8%) of the infants; 35% of the colonized women had colonized infants.

The frequency of the group B subtypes is shown in Table I. All subtypes were seen. In eight instances the same subtype was detected in both mother and infant. In one instance subtype 1c was found in the mother and an "untypable" strain in the infant. This may have been a strain that had become untypable through loss on subculture of the type-specific capsular antigen, and this does not necessarily indicate a discrepancy between the serotypes of mother and infant.

Six infants were delivered by cesarean section from women in whom colonization by group B streptococci

was detected. The organism was isolated from four of the six infants, two of whom were delivered by elective cesarean section prior to rupture of the membranes and onset of labour.

In none of the infants did meningitis or septicemia develop.

### Discussion

The incidence of maternal and neonatal colonization with group B streptococci in the Ottawa region is comparable to that reported in the United States<sup>3</sup> and Great Britain.<sup>4</sup> We are aware of one previously published study from Canada, that of Embil, Belgaumkar and Macdonald,<sup>5</sup> who found a colonization rate for infants of 2.17% and did not report a corresponding maternal rate. They, however, examined only rectal swabs, which we did not include in our specimens from infants. The higher colonization rate in our group of infants, 8%, is probably partially related to the fact that swabs were taken from three areas — umbilicus, groin and ear — in our study.

Overt infection develops in approximately 1 of every 100 babies with group B streptococcal coloniza-

From the departments of pediatrics and laboratory medicine, Children's Hospital of Eastern Ontario, Ottawa

\*Current address: Department of infectious diseases, Montreal Children's Hospital

Reprint requests to: Dr. A.M.R. Mackenzie, Department of laboratory medicine, Children's Hospital of Eastern Ontario, 401 Smyth Rd., Ottawa, Ont. K1H 8L1

Table I—Subtypes of isolated group B streptococci

Source of organism	Subtype; no. of cases					Total no. of cases
	1a	1b	1c	2	3	
Mother and infant	2	0	1*	4	2	9
Mother only	0	3	2	4	8	17
Infant only	0	1	0	0	1	2

\*The mother's strain was type 1c, while the infant's was "untypable".

tion.<sup>6</sup> The prophylactic administration of antibiotics to all babies born of women with colonization and to all babies with colonization would mean the administration of approximately 100 to 200 unnecessary doses for each case of overt infection prevented. It is therefore essential to find some means of identifying more specifically the infants that are at high risk for sepsis. We believe, on the basis of the results of our study, that a positive culture of either vaginal swabs from the mother or swabs from the baby is not a selective enough criterion for a classification of high risk.

Baker and Kasper<sup>7</sup> have demonstrated that type-III-specific opsonic antibodies are absent in mothers of children with group B streptococcal colonization, and they are developing a vaccine containing the type-III-specific polysaccharide. It might also be possible to identify infants at high risk by examining the mother's serum for opsonins. This presently requires technologically demanding and expensive tests that are unsuitable for widespread routine use.

Four of the babies in our series with group B streptococcal colonization were delivered by cesarean section; in two instances the procedure was performed electively before rupture of the membranes. This lends support to the conclusion of Baker<sup>8</sup> that group B streptococcal infection in infants can occur in utero. This view is supported by the short interval (as little as 3 hours) between delivery and the recognition of symptoms that has been reported by others.<sup>9</sup> It is possible that well timed administration of penicillin might prevent colonization in utero, although it is not possible to cure established maternal colonization in this way.<sup>10</sup>

Pending the development and application of an effective vaccine, priority should be given to the development of tests for maternal type-specific opsonins suitable for large-scale use. With such tests it might be possible to recognize the small proportion of infants at high risk for sepsis rather than colonization and to take appropriate measures.

We thank Dr. R.H. Elder, Dr. H. Oxorn and the caseroom staff at the Ottawa Civic Hospital for their cooperation and support, and Ms. Laurie Pepin for technical assistance.

## References

1. BAKER CJ, CLARK DJ, BARRETT FF: Selective broth medium for isolation of group B streptococci. *Appl Microbiol* 26: 884, 1973
2. CHRISTIE R, ATKINS NE, MUNCH-PETERSEN E: A note on a lytic phenomenon shown by group B streptococci. *Aust J Exp Biol Med Sci* 22: 197, 1944
3. BAKER CJ, BARRETT FF: Transmission of group B streptococci among parturient women and their neonates. *J Pediatr* 83: 919, 1973
4. MHALU FS: Reservoir of group B streptococci in women in labour. *Br Med J* 1: 812, 1977
5. EMBIL JA, BELGAUMKAR TK, MACDONALD SW: Group B beta-hemolytic streptococci in an intramural neonatal population. *Scand J Infect Dis* 10: 50, 1978
6. ANTHONY BF, OKADA DM: Emergence of group-B streptococci in infections of the newborn infant. *Annu Rev Med* 28: 355, 1977
7. BAKER CJ, KASPER DL: Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. *N Engl J Med* 294: 753, 1976
8. BAKER CJ: Early onset group B streptococcal disease. *J Pediatr* 93: 124, 1978
9. ABLow RC, DRISCOLL SG, EFFMANN EL, et al: A comparison of early-onset group B streptococcal neonatal infection and the respiratory-distress syndrome of the newborn. *N Engl J Med* 294: 65, 1976
10. HALL RT, BARNES W, KRISHNAN L: Antibiotic treatment of parturient women colonized with group-B streptococci. *Am J Obstet Gynecol* 124: 630, 1976

## BOOKS

continued from page 1094

**MICROSURGICAL COMPOSITE TISSUE TRANSPLANTATION.** Edited by Donald Serafin and Harry J. Buncke, Jr. 791 pp. Illust. The C.V. Mosby Company, Saint Louis, Missouri, 1979. \$66.25. ISBN 0-8016-0882-1

**NURSING THEORY.** Analysis, Application, Evaluation. Barbara J. Stevens. 280 pp. Illust. Little, Brown and Company (Inc.), Boston, 1979. \$9.95. ISBN 0-316-08989-3

**PREOPERATIVE AND POSTOPERATIVE CARE IN NEUROLOGICAL SURGERY.** 2nd ed. Burton L. Wise. 187 pp. Charles C. Thomas, Publishers, Springfield, Illinois, 1978. \$13.75. ISBN 0-398-03825-2

continued on page 1119

The other side of depression.

# Anafranil®

## Antidepressant

**Indications and Clinical Uses** Anafranil (clomipramine hydrochloride) is indicated in the drug treatment of depressive illness, including manic depressive psychosis, depressed phase, and involuntional melancholia. Anafranil appears to have a mild sedative effect which may be helpful in alleviating the anxiety component often accompanying depression.

**Contraindications** Anafranil should not be given in conjunction with or within fourteen days of treatment with a monoamine oxidase inhibitor. Combined therapy of this type could lead to the appearance of serious hypertensive crises and death may occur.

Anafranil is contraindicated in patients with existing liver damage and should not be administered to patients with a history of blood dyscrasias.

Anafranil is contraindicated in patients who have shown hypersensitivity to the drug.

Anafranil is contraindicated in patients with glaucoma, as the condition may be aggravated due to the atropine-like effects of the drug.

**Use in Pregnancy:** The safety of use in pregnant women has not been established. Therefore, Anafranil should not be administered to women of childbearing potential, particularly during the first trimester of pregnancy, unless, in the opinion of the physician, the expected benefit to the patient outweighs the potential risk to the fetus.

**Warnings** The following warnings apply to Anafranil and other tricyclic antidepressant agents:

Tricyclic agents may lower the convulsive threshold and should, therefore, be used with caution in patients with convulsive disorders.

Electrocardiographic studies suggest that Anafranil should not be used in the presence of pronounced cardiac or circulatory failure, recent myocardial infarction or ischaemic heart disease. Anafranil also has a hypotensive action which may be detrimental in these circumstances. The drug should, therefore, be used with caution in patients who are susceptible to hypotensive episodes.

Tricyclic agents may produce urinary retention and should be used with caution in patients with urinary pathology, particularly in the presence of prostatic hypertrophy.

Particularly in the elderly and in hospitalized patients the tricyclic antidepressants may give rise to paralytic ileus and therefore appropriate measures should be taken if constipation occurs.

Anafranil should be kept in a safe place, well out of the reach of children.

**Precautions** In seriously depressed patients the possibility of suicide should be borne in mind and may persist until significant remission occurs. Therefore, these patients should be carefully supervised during treatment with Anafranil, and hospitalization or concomitant electro-convulsive therapy may be required.

Activation of latent schizophrenia or aggravation of existing psychotic manifestations in schizophrenic patients may occur; patients with manic-depressive tendencies may experience hypomanic or manic shifts; and hyperactive or agitated patients may become over-stimulated. A reduction in dose or discontinuation of Anafranil should be considered under these circumstances.

Since Anafranil may produce sedation, particularly during the initial phase of therapy, patients should be cautioned about the danger of engaging in activities requiring mental alertness, judgement and physical coordination.

It should be borne in mind that Anafranil may block the pharmacological effects of hypotensive drugs, such as guanethidine and similar agents.

Caution should be observed in prescribing Anafranil in hyperthyroid patients or in patients receiving thyroid medication conjointly. Transient cardiac arrhythmias have occurred in rare instances in patients who have been receiving other tricyclic compounds concomitantly with thyroid medication.

Obstructive jaundice and bone marrow depression with agranulocytosis have been reported. Periodic blood cell counts and liver function tests are recommended in patients receiving treatment with Anafranil over prolonged periods.

**Adverse Reactions** The following adverse reactions have been reported with Anafranil or other tricyclic antidepressants:

**Central Nervous System Effects:** drowsiness, fatigue, insomnia, extrapyramidal effects such as tremor and ataxia, headache, anorexia and convulsions. Peripheral neuropathy has also been reported with tricyclic compounds.

**Behavioural Effects:** agitation, excitement, hyperomania or manic episodes, activation of psychosis, confusion, disturbed concentration, visual hallucinations.

**Autonomic Nervous System Effects:** dry mouth, blurred vision, difficulty with accommodation, constipation, paralytic ileus, disturbances of micturition, excessive sweating, nausea and vomiting.

**Cardiovascular Effects:** hypotension, particularly orthostatic hypotension with associated vertigo, tachycardia, syncope, arrhythmia, asystole. EKG changes (including flattening or inversion of T wave) and disturbances in cardiac conduction.

**Haematological and Other Toxic Effects:** agranulocytosis has been reported; it represents a hypersensitivity reaction. Eosinophilia may also occur. Obstructive jaundice, allergic skin reactions, photosensitization, occasional disturbances of appetite, abdominal pain, changes in libido, and weight gain.

**Dosage and Administration** EXCEPT IN ELDERLY PATIENTS AND ADOLESCENTS: One tablet (25 mg) 3 times daily initially, increase up to six tablets (150 mg) daily, or more, as required.

Dosage in excess of 200 mg daily is not usually recommended for office patients. Occasionally in more severe hospitalized patients, dosages up to 300 mg may be required.

IN ELDERLY PATIENTS AND ADOLESCENTS: 20 to 30 mg daily, increased by 10 mg daily, if necessary, depending on tolerance and response.

**Availability** Each pale yellow, sugar-coated lenticular tablet branded (Geigy) contains 25 mg clomipramine hydrochloride.

Also available in pale yellow, triangular sugar-coated tablets branded (Geigy), containing 10 mg clomipramine hydrochloride.

In bottles of 50 and 500.

Product Monograph available to physicians and pharmacists on request.

### References:

1. Rompel, H.: The Treatment of Depression, *Med. Proc.* 73, 631, (1967)
2. Clarke, F. C.: The Treatment of Depression in General Practice. *S. Afr. Med. J.* 43, 23, (1969)
3. Lasich, A. J.: Clinical Evaluation of a New Anti-Depressant (Anafranil), *Med. Proc.* 74, 312 (1968)

## Geigy

Dorval, P.Q. H9S 1B1

G-7004R

See page 1109